Trial · NCT07894406
The Effect of a Ginger Formula on Menstrual Health vs a Placebo
NCT07894406, Not applicable, Not yet recruiting, Givaudan France Naturals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of a Ginger Formula on Menstrual Health vs a Placebo. Trials, record NCT07894406. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894406
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of a Ginger Formula on Menstrual Health vs a Placebo
- NCT number
- NCT07894406
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 250 participants, estimated
- Lead sponsor
- Givaudan France Naturals
- Conditions
- Painful Menstruation
- Interventions
- Ginger formula, Placebo
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in menstrual pain intensity VAS from Cycle 0 to Cycle 2. | Menstrual days 1-3 of Cycle 0 (baseline, no study product) and Cycle 2. Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Mean daily Visual Analogue Scale (VAS) pain intensity across menstrual days 1-3, Change from Cycle 0 to Cycle 2. VAS consists of a 100 mm line anchored by "no pain" (0 cm) and "pain as bad as it could be" (10 cm); scores reported in cm (0-10). |
| Secondary | Change in menstrual pain intensity VAS from Cycle 0 to Cycle 1. | Menstrual days 1-3 of Cycle 0 (baseline, no study product) and Cycle 1 (3 days after first dose). Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Mean daily Visual Analogue Scale (VAS) pain intensity across menstrual days 1-3, Change from Cycle 0 to Cycle 1. VAS consists of a 100 mm line anchored by "no pain" (0 cm) and "pain as bad as it could be" (10 cm); scores reported in cm (0-10). |
| Secondary | Change in menstrual pain duration (hours) from Cycle 0 to Cycle 1 and Cycle 2. | Daily throughout each menstruation period (Cycles 0-1-2), with previous-day symptom recall. Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Participants will report the total number of hours they experienced menstrual pain over the past 24 hours. Numeric entry : 0-24h. |
| Secondary | Change in menstrual rescue medicine use from Cycle 0 to Cycle 1 and Cycle 2. | Daily throughout each menstruation period (Cycles 0-1-2), with previous-day symptom recall. Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Participants will report whether they used acetaminophen over the past 24 hours. If yes, participants will report the dose (500 mg or 1000 mg) and the number of doses taken during the past 24 hours (1-4 doses). |
| Secondary | Change in menstrual bleeding flow from Cycle 0 to Cycle 1 and Cycle 2. | Daily throughout each menstruation period (Cycles 0-1-2), with previous-day symptom recall. Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Menstrual flow over the past 24 hours will be assessed using a single categorical item, with response options of light, moderate, heavy, or my period has ended. |
| Secondary | Change in the Verbal Multidimensional Scoring system (VMS) from Cycle 0 to Cycle 1 and Cycle 2. | Retrospective assessment of the preceding menstrual period, completed the day after menstruation ends (Cycles 0, 1, and 2). Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | VMS provides categorical assessment of menstrual pain severity across four grades (0-3): Painless menstruation =0, menstruation with pain but rare use of analgesics or limitation of activities =1, menstruation with moderate pain with influence on daily activities and use of analgesics with relief =2, and menstruation with severe pain with significant limitations on daily activities, ineffective use of analgesics, and such symptoms as headache, tenderness, nausea, vomiting, and diarrhea =3. Participants select the grade description that best matches their experience during the entire past menstruation phase. |
| Secondary | Change in menstrual gastrointestinal symptoms NRS from Cycle 0 to Cycle 1 and Cycle 2. | Retrospective assessment of the preceding menstrual period, completed the day after menstruation ends (Cycles 0, 1, and 2). Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Individual gastrointestinal symptoms, including bloating, nausea, and transit disturbances (diarrhea/constipation), will be evaluated using a Numeric Rating Scale (NRS; 0 = none, 10 = worst possible). Scores will be analyzed on a per-item basis. |
| Secondary | Change in menstrual physical symptoms NRS from Cycle 0 to Cycle 1 and Cycle 2. | Retrospective assessment of the preceding menstrual period, completed the day after menstruation ends (Cycles 0, 1, and 2). Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Individual physical symptoms, including headache, fatigue, and muscle/bone/joint pain, will be evaluated using a Numeric Rating Scale (NRS; 0 = none, 10 = worst possible). Scores will be analyzed on a per-item basis. |
| Secondary | Change in menstrual quality of life impact from Cycle 0 to Cycle 1 and Cycle 2. | Retrospective assessment of the preceding menstrual period, completed the day after menstruation ends (Cycles 0, 1, and 2). Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Quality of life impact will be evaluated through 3 individual items assessing the degree to which symptoms interfere with work/school participation, relationships, and enjoyment of life, using a 5-point frequency scale (Never, Rarely, Sometimes, Often, Always). Individual item scores will be analyzed separately. |
| Secondary | Change in premenstrual physical symptom NRS from Cycle 0 to Cycle 1 and Cycle 2. | Retroactively at Day 1 of Cycle 1 and 2, covering the preceding 14-day premenstrual phase. Cycle length and menstruation duration are participant- and cycle-dependent, ranging from 21-35 d and 3-7 d, respectively. | Physical symptom severity during the premenstrual phase will be assessed through 5 individual items evaluating bloating, nausea, breast tenderness, headaches, and muscle/bone/joint pain. Responses will be recorded on a Numeric Rating Scale (NRS; 0 = none, 10 = worst possible severity). Scores will be analyzed on a per-item basis. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894406
GET https://conductscience.org/api/trials/v1/NCT07894406/registered